Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBO MMRd-GREEN durvalumab adjuvant trial in molecularly classified high-risk endometrial cancer
NL-OMON54178Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of durvalumab in endometrial cancer (EC) and endometrial carcinosarcoma, sponsored by Leiden University Medical Center. Started Aug 2022; status: recruiting.
02
Drugs
durvalumab
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on NL-OMON54178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54178.